Notice for BNT162b2[mRNA] (Pfizer Australia Pty Ltd)
Active ingredients
BNT162b2[mRNA]
Sponsor
Date of review outcome
Lapse date
Type
Provisional approval
Indication
Active immunisation against COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 12 years and older.
Therapeutic area
Infectious diseases